Question-and-Answer Session
Operator
(Operator Instruction). We will go first to Richard Smith-JP Morgan.
Richard Smith
(Inaudible)
Unidentified Company Representative
Richard, can you speak up please.
Richard Smith
Can you hear me now?
Unidentified Company Representative
Yes, that's better.
Richard Smith
Okay. Sorry about that. So I was just wondering on 543. I know – as you said, whether you are going into the Phase 2 with the 400 mg or the 200 mg, and maybe can you provide any update on the – you said some prolonged stable disease in prior presentation. Any update there?
John Yates
Yes. A 400 mg twice daily is a maximum tolerated dose determined from the dose escalation Phase of Phase1, and that dose is providing us with very good exposure over the entire 24 hour period.
Richard Smith
Okay. Any update on the dates we presented back at AACR.
John Yates
Well at that time, we have not achieved the maximum tolerated dose. So, I think that's the major update now that we have identified that and are well in the expansion phase, and obviously as we get more experienced in the expansion phase that can provide us some signals that may help guide our future development.
Richard Smith
Just one last question. With respect to the dental pain market, have you done any work there? Can give us some sense of how big that market could be?
John Yates
Yes, dental pain represents about 15% of the total acute pain market and so, therefore it's a relatively significant segment in an off itself. But I think we are looking at the dental pain model as a tried and true way to assess pain relatively quickly and inexpensively the analgesic potential of the drug. And then, once we have done that and seen how effective we are relative to placebo and dose range and potentially relative to comparators agents, then we will know how likely it is that we can progress for a broader pain indication and one that we are contemplating right now is a postoperative pain indication, because of the unmet medical need in that area, but clearly once you have a drug with analgesic efficacy, we can think in the future of other types of painful condition.
Richard Smith
Okay, thank you.
John Yates
Thanks Richard
Operator
Next we moved to Ed Tenthoff of Piper Jaffray
Edward Tenthoff.
Great. Thank you very much. Just following up quickly on the 797, did you say that when should we be getting that Phase 2 dental pain data?
- To read the full transcript on Seeking Alpha, click here »
